Close Menu

NEW YORK ─ Trinity Biotech said on Tuesday that its second quarter 2020 revenues dropped 29 percent year over year, partly due to the adverse impact of COVID-19 on its diabetes, autoimmune, and infectious disease revenues.

For the three months ended June 30, the diagnostic company posted revenues of $16 million compared to $22.5 million in the prior-year quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.